Effects of purified Omphalia lapidescens protein on metastasis, cell cycle, apoptosis and the JAK-STAT signaling pathway in SGC-7901 human gastric cells
- Luchao Chen
- Zhongxia Lu
- Yongle Yang
- Lijun Du
- Xiaofang Zhou
- Yitao Chen
Published online on: January 19, 2018
Copyright: © Chen et al.
This is an open access article distributed under the terms of Creative Commons Attribution License.
Gastric cancer is one of the most common cancers globally with high rates of morbidity and mortality. Purified Omphalia lapidescens protein (pPeOp) is a protein extracted from the sclerotium of Omphalia lapidescens. The present study aimed to investigate the effects of pPeOp on the viability, migration, cell cycle progression and apoptosis of SGC‑7901 cells. The expression of numerous proteins, namely matrix metallopeptidase (MMP)2, MMP9, p53, caspase‑3, B‑cell lymphoma (Bcl)‑2, cyclin A2, cyclin B1, cyclin D1, cyclin dependent kinase (CDK)1, CDK2 and CDK4, were investigated using western blot analysis and reverse transcription‑quantitative polymerase chain reaction. The results of the present study demonstrated that treating SGC‑7901 cells with pPeOp markedly suppressed their migration, induced their apoptosis and arrested their progression in S phase. pPeOp also downregulated the expression of migration‑associated proteins (MMP2 and MMP9) and cyclin‑associated proteins (cyclin A2, cyclin B1, cyclin D1, CDK1, CDK2 and CDK4) in a dose‑dependent manner. Cells treated with pPeOp significantly upregulated caspase‑3 and p53 and downregulated Bcl‑2. Finally, the impact of pPeOp on three key nodes of the Janus kinase (JAK)‑signal transducer and activator of transcription (STAT) pathway were investigated and it was revealed that expression levels of JAK1, JAK2 and STAT3 were significantly downregulated following treatment. Together, the results of the present study suggested that pPeOp suppresses metastasis, arrests cell cycle, induces apoptosis and inhibits the JAK‑STAT signaling pathway in SGC‑7901 cells. Therefore, pPeOp may serve as a novel therapeutic agent for patients with gastric cancer.